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Com o propósito de aumentar a atividade anticâncer demonstrada anteriormente pelas 
1-fenilssubstituído-3-(2-tioxo-1,3,4-oxadiazol-5-il) b-carbolinas 1a-c, neste trabalho foram 
realizadas a síntese e a avaliação in vitro da atividade antitumoral de novas bases de Mannich 2-7(a-c), 
derivadas da introdução de diferentes grupos alquilamino(metil) na unidade 1,3,4-oxadiazol de 
1a-c. Os derivados 1a-c e 2-7(a-c) foram também avaliados quanto às atividades antibacteriana e 
antifúngica. Adicionalmente, um estudo in silico das propriedades de ADME dos novos compostos 
sintetizados 2-7(a-c) foi realizado pela avaliação de seus parâmetros de Lipinski e de dados de 
área de superfície topológica polar (TPSA) e de porcentagem de absorção (% ABS).
With the purpose of activity enhancement of 1-substituted phenyl-3-(2-thioxo-1,3,4-oxadiazol-
5-yl) b-carbolines 1a-c, reported as potential antitumor agents in our previous study, herein we 
report the synthesis and antitumor activity evaluation of several novel Mannich bases 2-7(a-c), by 
the introduction of different alkylamino(methyl) groups in the 1,3,4-oxadiazole unity of 1a-c. The 
antimicrobial activities of 1a-c and of 2-7(a-c) were also evaluated. Additionally, an in silico study 
of the ADME properties of novel synthesized b-carboline derivatives 2-7(a-c) was performed by 
evaluation of their Lipinski’s parameters and topological polar surface area (TPSA) and percentage 
of absorption (% ABS) data.
Keywords: 1,3-disubstituted b-carboline derivatives, 1,3,4-oxadiazole, Mannich bases, 
antitumor activity, antimicrobial activity
Introduction
b-Carboline alkaloids are a class of synthetic and 
naturally occurring compounds that possess a large 
spectrum of important pharmacological properties.1 
Particularly, these compounds have shown antitumor 
activity,1-10 acting mainly as intercalating into DNA.6-10 Also, 
synthetic and natural compounds of this class exhibited 
antimicrobial activities, mainly against Bacillus subtilis, 
Escherichia coli and Staphylococcus aureus bacteria and 
against Candida albicans fungi.11-13
Studies on a variety of synthetic b-carboline derivatives 
have demonstrated the influence of both molecule planarity 
and substituents nature in C-1, C-3 and position -9 of 
the b-carboline skeleton on activity.4,5 The presence of 
appropriate substituents on these positions could lead to 
more potent compounds with reduced toxicity. 
The biological potential of b-carboline alkaloids 
and the importance of the search for new antitumor and 
antimicrobial agents have led us to study this class of 
compounds. In previous work, we reported synthesis and in 
vitro antitumor activities of a series of 1-substituted phenyl 
b-carboline bearing 2-thioxo-1,3,4-oxadiazol-5-yl moiety 
at C-3.14 The anticancer assay results pointed compounds 
1a-c with growth inhibition effect (GI50 < 100 mmol L-1) 
for all eight human cancer cell lines tested.14 
Taking in account our previous results and with the aim 
of increasing the antitumor activity we have continued our 
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work on b-carboline derivatives 1, with the introduction of 
substituents in 1,3,4-oxadiazole ring. Literature reports that 
Mannich bases of oxadiazoles possess important activities, 
such as antibacterial and anticancer.15-17
Therefore, in this study we synthesized six series 
of Mannich bases from the previously reported active 
compounds 1a-c14 to investigate the effects of different 
3-alkylamino(methyl) substituents on the oxadiazole ring, 
expecting that the incorporation of these substituents 
would lead to antitumor activity enhancement. More 
specifically, we report the synthesis and in vitro anticancer 
activity of b-carboline derivatives 2-7(a-c) bearing a 
3-alkylamino(methyl)-2-thioxo-1,3,4-oxadiazol-5-yl group 
at C-3. Additionally, the antimicrobial activities of 1a-c and 
of the Mannich bases 2-7(a-c) were evaluated. 
An in silico study of the ADME properties of novel 
synthesized b-carboline derivatives was carried out by 
investigation of their Lipinski’s parameters, topological 
polar surface area (TPSA) and percentage of absorption 
(% ABS).18,19
Results and Discussion 
Chemistry
The 3-(2-thioxo-1,3,4-oxadiazol-5-yl) b-carbolines 
1a-c were prepared from the commercial L-tryptophan 
as previously reported.14 The condensation reaction of 
1a-c, formaldehyde 37%15,17 and the primary amines 
isopropylamine, butylamine, cyclohexylamine and 
benzylamine, using ethanol as solvent, afforded the 
Mannich bases 2a-c, 3a-c, 4a-c and 5a-c, respectively 
(Scheme 1). Condensation reaction with pyrrolidine and 
morpholine secondary amines under the same conditions, 
afforded the Mannich bases 6a-c and 7a-c, respectively 
(Scheme 1). The Mannich bases 2-7(a-c) were obtained 
in range of 52% to 92% yields from 1a-c, and in six steps 
from commercial L-tryptophan with 15-34% overall yields.
All novel compounds were characterized by their 
spectroscopic data (IR, EIMS, 1H and 13C NMR), which 
are described in the Experimental section. 
The formation of Mannich bases 2-7(a-c) was 
evidenced by the presence of a singlet at dH 5.00-6.00 in the 
1H NMR spectra, corresponding to the methylene exocyclic 
hydrogens of the alkylamino(methyl) group introduced at 
N-3 of the 1,3,4-oxadiazole ring, together with the signals 
for each group alkylamino. The exocyclic methylene carbon 
of the alkylamino group appears in the region of dC 60-70 
in the 13C NMR. The signals in the dC 177 and 160 region 
were assigned for C-2 and C-5 carbons, respectively, of the 
1,3,4-oxadiazole ring.
The IR spectra showed absorption bands characteristic 
for N-H indole and C=N stretching in the 3040 and 
1615 cm-1 region, respectively, and for C=S group at 1390 
and 1240 cm-1.
The structures of 2-7(a-c) were also confirmed by EI 
mass spectra. The majority of compounds showed the 
presence of a base peak at m/z [M+·- alkylamino(methyl)-
Scheme 1. Synthesis of compounds 2-7 (a-c).
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Table 1. GI50 values (in µmol L-1) and GI50 MG-MID (in µmol L-1) for compounds 1a-c and 2-7(a-c)



















Doxorubicin 0.43 0.005 0.13 0.21 0.04 0.46 0.34 0.46 0.14
1a >100 25.54 17.60 27.95 20.60 25.54 31.77 25.54 29.25
1b 24.10 27.93 74.99 32.38 73.41 12.20 22.31 27.93 31.26
1c 23.82 18.84 32.11 14.72 19.09 14.72 14.72 40.46 20.83
2a 6.00 0.86 5.90 4.66 5.72 6.12 6.21 43.85 5.89
2b 7.08 4.56 9.27 49.90 4.26 53.54 6.25 >100 14.79
2c 0.88 5.88 2.78 9.82 1.01 13.31 3.42 22.06 4.37
3a 5.29 7.29 30.16 6.51 2.74 26.66 5.99 49.80 10.72
3b >100 >100 >100 >100 >100 >100 >100 >100 100.00
3c 10.34 42.04 16.32 5.03 3.99 35.24 39.05 >100 19.50
4a 8.89 40.79 13.49 28.57 7.02 38.99 11.21 >100 21.38
4b 7.58 14.33 3.74 49.81 4.33 20.31 12.28 >100 14.79
4c 8.74 >100 5.13 52.44 15.19 58.48 18.66 >100 28.18
5a >100 16.87 3.72 1.31 4.63 47.68 6.39 54.29 12.59
5b 11.30 16.64 5.34 7.13 5.25 14.17 5.55 68.52 10.96
5c 2.98 10.23 2.55 0.38 1.28 14.96 5.91 56.34 4.57
6a 7.61 22.81 6.83 9.45 7.58 22.64 6.97 21.53 11.48
6b 6.97 11.23 6.65 15.98 17.98 14.25 6.51 24.15 11.75
6c 6.63 16.08 7.05 21.81 11.04 11.00 5.96 14.13 10.72
7a 6.77 39.43 7.59 11.42 36.77 8.10 7.38 17.61 13.18
7b 6.81 11.49 7.96 51.73 40.43 6.33 10.38 38.91 15.49
7c 24.19 56.35 20.16 67.63 38.55 16.58 47.33 49.28 36.31
aGI50 mean-graph midpoint (MG-MID) = average sensitivity of all cell lines toward the test compounds.
thioxo-1,3,4-oxadiazole] relative to cleavage between C-3 
of b-carboline and C-5 of 1,3,4-oxadiazole ring. For the 
benzyl derivatives 5a-c the base peaks were observed at 
m/z 91, which was due to the tropilium ion formation. 
Anticancer activity
The GI50, TGI and LC50 data and MG-MID values 
obtained for each compound and cell lines tested were 
summarized in Tables 1 and 2. The anticancer assay results 
pointed towards eleven compounds (2a, 2c, 3a, 5b, 5c, 6a-c 
and 7a-c) with growth inhibition effect (GI50 < 100 mmol L-1) 
for all eight human cancer cell lines tested, showing GI50 
(MG-MID) values within 4.37 to 36.31 mmol L-1 range 
(Table 1). Analysis of the TGI (MG-MID) values (Table 2) 
showed that the Mannich bases synthesized were able to 
inhibit total growth (cytostatic activity), except for 3b and 
7c, in a concentration minor than 100 mmol L-1.
Among compounds tested, 2a, 2c and 5c were the 
most active derivatives, exhibiting a broad antitumor 
activity spectrum at GI50 and TGI levels, with GI50 (MG-
MID) values of 5.89, 4.37 and 4.57 mmol L-1 (Table 1), 
respectively. Moreover, compound 2a displayed cytotoxic 
efficacy with LC50 (MG-MID) value of 60.49 mmol L-1 
(Table 2). 
A potent activity against melanoma (UACC-62) and 
lung (NCI-460) cell lines, with GI50 values of 0.88 and 
1.01 mmol L-1 (Table 1), respectively, was observed for 
compound 2c, which possess the N,N-dimethylphenyl 
and isopropylamino(methyl) groups at C-1 and C-3, 
respectively, of the b-carboline nucleus. Compound 5c 
also demonstrated a significant activity, with GI50 values in 
the range of 0.38 and 2.98 µmol L-1 towards four cell lines 
(melanoma, ovarian resistant, renal and lung).
Comparison of the GI50 (MG-MID) values for all tested 
compounds showed that, except for 3b, 4c and 7c, the 
Mannich bases derivatives displayed higher anticancer 
activity than the corresponding precursors. For the most 
active 2a, 2c and 5c Mannich bases, the introduction of an 
alkylamino(methyl) group at N-3 of the heterocyclic ring 
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Table 2. TGI (in µmol L-1) and LC50 (in µmol L-1, values in parentheses) and TGI and LC50 MG-MID (µmol L-1) for compounds 1a-c and 2-7(a-c)
















Colon    
HT29
MG-MIDa
Doxorubicin 0.44 (0.99) 0.09 (2.78) 6.14 (68.44) 10.00 (>100) 1.25 (>100) 4.59 (82.12) 2.61 (>100) 10.58 (>100) 2.09 (33.37)
1a >100 >100 >100 >100 >100 >100 >100 >100 >100 (>100)
1b >100 >100 >100 >100 >100 35.77(>100) >100 >100 87.1 (>100)
1c >100 >100 >100 >100 >100 >100 >100 >100 >100 (>100)
2a 15.63 (56.88) 16.01 (74.61) 20.10 (63.05) 3.96 (20.62) 17.63 (61.95) 30.91 (>100) 14.64 (52.41) 81.39 (>100) 18.36 (60.49)
2b >100 98.35 (>100) >100 >100 88.90 (>100) >100 67.50 (>100) >100 93.62 (>100)
2c 6.81 (>100) >100 39.16 >100 >100 >100 95.97 (>100) >100 63.25 (>100)
3a 15.12 (58.99) >100 >100 43.71 (>100) >100 >100 25.59 (>100) >100 60.05 (93.62)
3b >100 >100 >100 >100 >100 >100 >100 >100 >100 (>100)
3c 57.49 (>100) >100 >100 21.55 (>100) >100 >100 >100 >100 77.03 (>100)
4a 32.14 (52.07) >100 >100 >100 >100 >100 >100 >100 86.77 (92.17)
4b 65.59 (48.62) >100 >100 >100 >100 >100 >100 >100 94.86 (92.17)
4c 35.12 (>100) >100 >100 >100 >100 >100 >100 >100 87.74 (>100)
5a 91.16 (>100) 66.96 (>100) 37.97 (>100) 12.94 (52.62) 39.85 (>100) 72.49 (>100) 34.54 (>100) >100 48.36 (92.29)
5b 53.52 (>100) 68.48 (>100) 52.52 (>100) 21.66 (41.14) >100 56.83 (>100) 22.25 (>100) >100 51.91 (89.49)
5c 58.52 (>100) >100 94.87 (>100) 19.62 (>100) >100 >100 58.91 (>100) >100 70.94 (>100)
6a 34.17 (>100) >100 51.40 (>100) >100 >100 72.79 (>100) 27.24 (57.73) 75.33 (>100) 63.44 (93.36)
6b 21.31 (47.18) >100 46.48 (>100) >100 >100 >100 21.53 (49.91) 91.41 (>100) 61.13 (83.18)
6c 25.34 (52.70) >100 91.37 (>100) 77.82 (>100) 71.19 (>100) 60.35 (>100) 24.81 (>100) 65.45 (>100) 57.86 (93.33)
7a 26.24 (53.19) >100 >100 37.81 (>100) >100 63.76 (>100) 28.81 (56.37) 71.36 (>100) 58.11 (86.02)
7b >100 >100 >100 >100 46.84 (>100) 30.11(>100) 44.97(69.85) 57.36 (>100) 66.09 (95.61)
7c >100 >100 >100 >100 >100 >100 >100 >100 >100 (>100)
aTGI and LC50 mean-graph midpoint (MG-MID) = average sensitivity of all cell lines toward the test compounds.
improved antitumoral activity 4.5 timefold compared to 
those of the 1,3,4-oxadiazoles 1a and 1c. Also, concerning 
to the effect of the different alkylamino groups on activity 
we observed that the isopropylamino(methyl) and 
benzylamino(methyl) substituents were the best choice for 
an increase of activity. 
Antimicrobial activity
Compounds 1a-c and their Mannich bases 2-7(a-c) were 
assayed against the bacteria Bacillus subtilis ATCC 2576, 
Escherichia coli ATCC 25922, Pseudomonas aeruginosa 
ATCC 13388, Sthaphylococus aureus ATCC 6538; and 
against the fungi Candida albicans ATCC 10231, Candida 
parapsilosis ATCC-22019 and Candida tropicalis ATCC-
28707.
The bioassays results for compounds 1a-c showed a 
potent antifungal activity for compound 1b against the 
Candida albicans fungi, with MIC value of 3.1 mg mL-1 
This derivative and the compound 1a were weakly active 
towards the bacteria B. subtilis (MIC = 250 mg mL-1). 
For the Mannich bases 2-7(a-c) none of the derivatives 
presented activity at the maximum concentration tested 
(250 mg mL-1), which demonstrated that the introduction of 
alkylamino(methyl) groups at the oxadiazole ring of 1a-c 
did not contribute for antimicrobial activity. 
In silico study 
An in silico computational study of the synthesized 
1-phenyl substituted-3-(3-alkylaminomethyl-2-thioxo-1,3,4-
oxadiazol-5-yl) b-carbolines 2-7(a-c) was performed by 
determination of Lipinski’s parameters, topological polar 
surface area (TPSA) and percentage of absorption (% ABS). 
Calculations were performed using “Molinspiration online 
property calculation toolkit” (http://www.molinspiration.
com)20 and “OSIRIS property explorer” (www.organic-
chemistry.org/prog/peo).21 The percentage of absorption was 
estimated using equation: %ABS = 109 - 0.345 × TPSA, 
according to Zhao et al.19 These data are shown in Table 3. 
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Table 3. Lipinsk´s parameters and %ABS, TPSA, Log S for compounds 2-7 (a-c)
Comp % ABS TPSA (Å²) Lipinski’s parameters Log S
nALH  acceptors nDLH  donors milogP MW n  violations
2a 84.27 71.68 6 2 4.31 415.52 0 -6.51
2b 68.46 117.50 9 2 4.27 460.52 0 -6.97
2c 83.15 74.91 7 2 4.42 458.59 0 -6.55
3a 84.27 71.676 6 2 5.08 429.55 1 -6.67
3b 68.46 117.5 9 2 5.04 474.55 1 -7.13
3c 83.15 74.914 7 2 5.18 472.62 1 -6.71
4a 84.27 71.68 6 2 5.55 455.59 1 -7.41
4b 68.46 117.50 9 2 5.50 500.58 2 -6.38
4c 83.15 74.91 7 2 5.65 498.66 1 -7.44
5a 84.27 71.68 6 2 5.04 463.57 1 -7.16
5b 68.46 117.50 9 2 5.00 508.56 1 -6.38
5c 83.15 74.91 7 2 5.14 506.64 2 -7.19
6a 87.3 62.89 6 1 4.29 427.53 0 -6.16
6b 71.49 108.71 9 1 4.25 472.53 0 -6.62
6c 86.19 66.13 7 1 4.39 470.60 0 -6.19
7a 84.12 72.12 7 1 3.73 443.53 0 -5.54
7b 68.31 117.95 10 1 3.69 488.53 0 -6.00
7c 83.00 75.36 8 1 3.83 486.60 0 -5.57
In vivo absorption of the new synthesized derivatives 
was tentatively assessed by means of theoretical calculations 
following Lipinski’s rule of five, which establishes that 
the absorption or permeation of an orally administered 
compound is more likely to be good if the drug satisfies 
the following criteria: (i) hydrogen bond donors ≤ 5 
(OH and NH groups); (ii) hydrogen bond acceptors ≤ 10 
(N and O atoms); (iii) molecular weight < 500; (iv) 
calculated log P < 5.18-20 Compounds violating more than 
one of these rules may present bioavailability problems. 
Our results (Table 3) revealed that the Mannich base 
derivatives containing the isopropylamino(methyl) (2a-c), 
pyrrolidyl(methyl) (6a-c) and morpholyl(methyl) (7a-c) 
groups attached to the 1,3,4-oxadiazole ring presented 
lipophilicity minor than 5, with values between 3.69 and 
4.41. On the other hand, the derivatives containing the 
butylamino(methyl) (3a-c), cyclohexylamino(methyl) 
(4a-c) and benzylamino(methyl) (5a-c) groups showed 
lipophilicity larger than 5.0, violating one of the Lipinski’s 
rules.
Except for 4b, 5b e 5c the molecular weight were minor 
than 500 (415.52 > MW < 498.65). All Mannich base 
derivatives have number of hydrogen bond acceptors (n-
ON = 6-10) and donors (n-OHNH = 1-2) in agreement with 
Lipinski’s rule. The calculated percent absorption (% ABS) 
of all derivatives ranged between 68.31 and 87.30 %, 
indicating that these compounds have a good permeability 
in the cellular plasmatic membrane. In summary, in silico 
study pointed the Mannich bases synthesized in our work 
as potential candidates for new antitumor agents.
Conclusions 
In conclusion, several 1-substituted phenyl-b-carbolines 
containing a 3-alkylamino(methyl)-2-thioxo-1,3,4-
oxadiazolyl group were prepared and identified as novel 
antitumor agents. Compounds 2a, 2c and 5c were the most 
active derivatives, exhibiting a broad spectrum antitumor 
activity at GI50 and TGI levels. Except for 3b, 4c and 7c, 
the Mannich base derivatives displayed higher anticancer 
activity than their corresponding precursors. For the most 
active Mannich bases 2a, 2c and 5c, the introduction of an 
alkylamino(methyl) group at N-3 of the heterocyclic ring 
improved antitumor activity 4.5 timefold compared to those 
of the 1,3,4-oxadiazoles 1a and 1c. 
The antimicrobial bioassays results showed that, among 
all tested compounds, only compound 1b was active, 
displaying potent activity against the yeast C. albicans.
Finally, in silico study pointed the novel derivatives as 
potential candidates for new drugs.
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Experimental
General
1H and 13C spectra were recorded in a Varian spectrometer 
model Mercury plus BB at 300 MHz and 75.5 MHz, 
respectively, with DMSO-d6 as solvent and TMS as the 
internal standard. Mass spectra (MS) were recorded in a 
Thermoelectron Corporation Focus-DSQ II spectrometer. 
IR spectra were recorded on a BOMEM spectrometer 
model MB-100. For TLC, Merck precoated plates 
(silica gel 60 G254) were used. Silica gel 60 Merck 
(230-400 mesh) was used in column chromatography 
purification of some compounds. All reagents were 
purchased from commercial suppliers. 




5-yl) b-carbolines 1a-c were prepared as previously 
reported.14
To a solution of derivatives 1a-c (0.5 mmol) in ethanol 
(10 mL) the primary or secondary amines (0.5 mmol) were 
added, followed of the dropwise addition of formaldehyde 
(37%, 3.0 mmol). The solution was stirred for 24 h at 60 oC 
and then, for 1h at 0 oC. The precipitated solid was filtered 
under vacuum suction and washed with cold ethanol. The 
characterization data of the Mannich bases obtained are 
given bellow. 
1-Phenyl-3-[3-isopropylamino(methyl)-2-thioxo-1,3,4-
oxadiazol-5-yl] b-carboline (2a) 
Yield: 62%, mp 234.0-237.0 oC. IR (KBr) n
max 
/cm-1: 
3040 (N–H), 1614 (C=N), 1360 and 1239 (C=S), 1565, 
1487 and 1464 (C=C). 1H NMR (300 MHz, DMSO-d6): 
d 8.94 (s, 1H, H-4), 8.47 (d, J 7.8 Hz, 1H, H-5), 7.35 (t, J 
7.8 Hz, 1H, H-6), 7.57-7.73 (m, 5H, H-7, H-8, H-3’, H-4’ 
and H-5’), 12.00 (s, 1H, NH-9), 8.09 (d, J 6.9 Hz, 2H, H-2’ 
and H-6’), 5.99 (brs, 2H, CH2-exocyclic), 11.43 (brs, 1H, 
NH-isopropyl), 4.60 (hep, J 6.9 Hz, 1H, CH-isopropyl), 
1.22 (d, J 6.9 Hz, 6H, CH3-isopropyl). 13C NMR (75.5 MHz, 
DMSO-d6): d 141.06 (C-1), 138.9 (C-3), 115.9 (C-4), 128.8 
(C-4a), 121.1 (C-4b), 122.2 (C-5), 120.5 (C-6), 129.2 (C-
7), 112.8 (C-8), 140.4 (C-8a), 133.9 (C-9a), 129.9 (C-1’), 
128.5 (C-2’/6’), 129.0 (C-3’/5’), 128.9 (C-4’), 174.3 (C-2”), 
159.7 (C-5”), 64.6 (CH2-exocyclic), 46.2 (CH-isopropyl), 
18.9 (CH3-isopropyl). EIMS, 70 eV, m/z (rel. int., %): 




Yield: 89%, mp 236.0- 237.0 oC. IR (KBr) n
max
/cm-1: 
3054 (N–H), 1611 (C=N), 1350 and 1239 (C=S), 1566, 
1485 and 1465 (C=C). 1H NMR (300 MHz, DMSO-d6): d 
9.01 (s, 1H, H-4), 8.55 (d, J 7.8 Hz, 1H, H-5), 7.37 (t, J 7.8 
Hz, 1H, H-6), 7.63-7.73 (m, 2H, H-7, H-8), 12.17 (s, 1H, 
9-NH), 8.83 (s, 1H, H-2’), 8.51 (d, J 7.8 Hz, H-4’), 7.97 
(t, J 7.8 Hz, H-5’), 8.44 (dd, J 7.8 Hz, 1.8 Hz, H-6’), 6.00 
(brs, 2H, CH2-exocyclic), 11.46 (brs, 1H, NH-isopropyl), 
4.63 (hep, J 6.9 Hz, 1H, CH-isopropyl), 1.23 (d, J 6.9 Hz, 
6H, CH3-isopropyl). 13C NMR (75.5 MHz, DMSO-d6): d 
141.7 (C-1), 137.9 (C-3), 116.7 (C-4), 130.5 (C-4a), 121.0 
(C-4b), 122.4 (C-5), 120.7 (C-6), 129.2 (C-7), 112.7 (C-8), 
139.09 (C-8a), 139.0 (C-9a), 134.1 (C-1’), 123.3 (C-2’), 
148.3 (C-3’), 123.6 (C-4’), 130.5 (C-5’), 134.9 (C-6’), 
174.3 (C-2”), 159.9 (C-5”), 64.6 (CH2-exocyclic), 46.2 
(CH-isopropyl), 18.9 (CH3-isopropyl). EIMS, 70 eV, m/z 









3085 (N–H), 1609 (C=N), 1365 and 1240 (C=S), 1557, 
1488 and 1466 (C=C). 1H NMR (300 MHz, DMSO-d6): 
d 8.82 (s, 1H, H-4), 8.42 (d, J 7.8 Hz, 1H, H-5), 7.32 (t, 
J 7.8 Hz, H-6), 7.60 (t, J 7.8 Hz, H-7), 7.72 (d, J 7.8 Hz, 
H-8), 11.87 (s, 1H, 9-NH), 7.95 (d, J 8.7 Hz, 2H, H-2’ and 
H-6’), 6.96 (d, J 8.7 Hz, 2H, H-3’ and H-5’), 3.05 (s, 6H, 
N(CH3)2), 5.98 (brs, 2H, CH2- exocyclic), 11.40 (brs, 1H, 
NH-isopropyl), 4.61 (hep, J 6.6 Hz, 1H, CH-isopropyl), 
1.24 (d, J 6.6 Hz, 6H, CH3-isopropyl). 13C NMR (75.5 
MHz, DMSO-d6): d 141.5 (C-1), 138.7 (C-3), 114.7 (C-
4), 124.9 (C-4a), 121.2 (C-4b), 122.0 (C-5), 120.3 (C-6), 
128.6 (C-7), 112.8 (C-8), 141.3 (C-8a), 133.5 (C-9a), 129.4 
(C-1’), 129.3 (C-2’), 112.2 (C-3’), 150.8 (C-4’), 112.2 
(C-5’), 129.3 (C-6’), 40.0 - N(CH3)2, 174.3 (C-2”), 166.7 
(C-5”), 64.6 (CH2-exocyclic), 46.2 (CH-isopropyl), 19.0 
(CH3-isopropyl). EIMS, 70 eV, m/z (rel. int., %): 458 (5, 
M+·), 344 (10), 287 (100), 242 (45), 121 (25), 100 (45).
1-Phenyl-3-[3-butylamino(methyl)-2-thioxo-1,3,4-
oxadiazol-5-yl]b-carboline (3a) 
Yield: 83%, mp 212.0-215.0 oC. IR (KBr) n
max
/cm-1: 
3057 (N–H), 1618 (C=N), 1394 and 1238 (C=S), 1566, 
1492 and 1456 (C=C). 1H NMR (300 MHz, DMSO-d6): 
d 8.93 (s, 1H, H-4), 8.46 (d, J 7.8 Hz, 1H, H-5), 7.35 (t, J 
7.8 Hz, 1H, H-6), 7.57-7.73 (m, 5H, H-7, H-8, H-3’, H-4’ 
and H-5’), 11.99 (s, 1H, 9-NH), 8.08 (d, J 6.9 Hz, 2H, H-2’ 
and H-6’), 5.92 (brs, 2H, CH2-exocyclic), 11.44 (brs, 1H, 
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NH-butyl), 3.58 (t, J 7.2 Hz, 2H, CH2-butyl), 1.56 (quint., 
J 7.2 Hz, 2H, CH2-butyl), 1.31 (sext., J 7.2 Hz, 2H, CH2-
butyl), 0.90 (t, J 7.2 Hz, 3H, CH3-butyl). 13C NMR (75.5 
MHz, DMSO-d6): d 141.6 (C-1), 138.9 (C-3), 115.9 (C-
4), 129.9 (C-4a), 121.1 (C-4b), 122.2 (C-5), 120.4 (C-6), 
129.2 (C-7), 112.8 (C-8), 140.5 (C-8a), 137.5 (C-9a), 133.9 
(C-1’), 128.5 (C-2’/6’), 129.0 (C-3’/5’), 128.9 (C-4’), 
175.5 (C-2”), 160.5 (C-5”), 68.0 (CH2-exocyclic), 43.9 
(CH2-butyl), 28.4 (CH2- butyl), 19.4 (CH2- butyl), 13.6 
(CH3-butyl). EIMS, 70 eV, m/z (rel. int., %): 429 (5, M+·), 
344 (25), 243 (100), 157 (15), 102 (15). 
1-(3-Nitrophenyl)-3-[3-butylamino(methyl)-2-thioxo-1,3,4-
oxadiazol-5-yl] b-carboline (3b)
Yield: 65%, mp 230.0-235.0 oC. IR (KBr) n
max 
/cm-1: 
3053 (N–H), 1612 (C=N), 1345 and 1238 (C=S), 1565 and 
1454 (C=C). 1H NMR (300 MHz, DMSO-d6): d 9.00 (s, 
1H, H-4); 8.55 (d, J 7.8 Hz,1H, H-5), 7.37 (t, J 7.8 Hz, 1H, 
H-6), 7.63 - 7.73 (m, 2H, H-7, H-8), 12.17 (s, 1H, 9-NH), 
8.83 (s, 1H, H-2’), 8.50 (d, J 8.0 Hz, 1H, H-4’), 7.96 (t, J 
8.0 Hz, 1H, H-5’), 8.43 (dd, J 8.0 and 2.1 Hz, 1H, H-6’), 
5.98 (brs, 2H, CH2-exocyclic), 11.47 (brs, 1H, NH-butyl), 
3.59 (t, J 7.2 Hz, 2H, CH2-butyl), 1.59 (quint., J 7.2 Hz, 2H, 
CH2-butyl), 1.31 (sext., J 7.2 Hz, 2H, CH2-butyl), 0.90 (t, J 
7.2 Hz, 3H, CH3-butyl). 13C NMR (75.5 MHz, DMSO-d6): 
d 141.7 (C-1), 138.9 (C-3), 116.7 (C-4), 121.0 (C0-4b), 
123.6 (C-5), 120.7 (C-6), 129.2 (C-7), 112.7 (C-8), 139.1 
(C-8a), 137.8 (C-9a), 134.1 (C-1’), 123.4 (C-2’), 148.3 (C-
3’), 122.4 (C-4’), 130.5 (C-5’), 134.8 (C-6’), 175.4 (C-2”), 
158.5 (C-5”), 68.5 (CH2-exocyclic), 44.1 (CH2-butyl), 28.3 
(CH2-butyl), 19.5 (CH2-butyl), 13.6 (CH3-butyl). EIMS, 
70 eV, m/z (rel. int., %): 474 (5, M+·), 242 (15), 157 (95), 
102 (75), 57 (100). 
1-(4-N,N-Dimethylaminophenyl)-3-[3-butylamino(methyl)-
2-thioxo-1,3,4-oxadiazol-5-yl] b-carboline (3c)
Yield: 92%, mp 214.0-216 oC. IR (KBr) n
max
/cm-1: 3262 
(N-H); 1608 (C=N); 1348 and 1229 (C=S), 1558, 1493 and 
1452 (C=C). 1H NMR (300 MHz, DMSO-d6): d 8.80 (s, 
1H, H-4), 8.42 (d, J 7.8 Hz, 1H, H-5), 7.32 (t, J 7.8 Hz, 1H, 
H-6), 7.60 (t, J 7.8 Hz, 1H, H-7), 7.71 (d, J 7.8 Hz, 1H, H-8), 
11.86 (s, 1H, 9-NH), 7.95 (d, J 8.7 Hz, 1H, H-2’), 6.96 (d, 
J 8.7 Hz, 1H, H-3’), 6.96 (d, J 8.7 Hz, 1H, H-5’), 7.95 (d, 
J 8.7 Hz, 1H, H-6’), 3.05 (s, 6H, N(CH3)2), 5.92 (brs, 2H, 
CH2-exocyclic), 11.41 (brs, 1H, NH-butyl), 3.59 (t, J 7.3 
Hz, 2H, CH2-butyl), 1.57 (quint., J 7.3 Hz, 2H, CH2-butyl), 
1.32 (sext., J 7.3 Hz, 2H, CH2-butyl), 0.92 (t, J 7.3 Hz, 3H, 
CH3-butyl). 13C NMR (75.5 MHz, DMSO-d6): d 141.4 (C-
1), 138.7 (C-3), 114.7 (C-4), 124.9 (C-4a), 121.2 (C-4b), 
122.0 (C-5), 120.3 (C-6), 128.6 (C-7), 112.8 (C-8), 141.3 
(C-8a), 129.3 (C-9a), 133.5 (C-1’), 129.3 (C-2’), 112.2 
(C-3’), 150.8 (C-4’), 112.2 -(C-5’), 129.3 (C-6’), 175.5 
(C-2”), 164.6 (C-5”), 40.0 - (CH3)2, 68.2 (CH2-exocyclic), 
44.0 (CH2-butyl), 28.5 (CH2-butyl), 19.5 (CH2-butyl), 13.7 
(CH3-butyl). EIMS, 70 eV, m/z (rel. int., %): 472 (5, M+·), 
242 (25), 157 (70), 84 (25), 76 (100).
1-Phenyl-3-[3-cyclohexylamino(methyl)-2-thioxo-1,3,4-
oxadiazol-5-yl] b-carboline (4a) 





3042 (N–H), 1613 (C=N), 1372 and 1237 (C=S), 1564, 
1484 and 1453 (C=C). 1H NMR (300 MHz, DMSO-d6): d 
8.94 (s, 1H, H-4), 8.45 (d, J 7.8 Hz, 1H, H-5), 7.35 (t, J 7.8 
Hz, 1H, H-6), 7.58 - 7.73 (m, 5H, H-7, H-8, H-3’, H-4’ and 
H-5’), 12.00 (s, 1H, 9-NH), 8.10 (d, J 6.9 Hz, 2H, H-2’ and 
H-6’), 6.00 (brs, 2H, CH2-exocyclic), 11.40 (brs, 1H, NH-
cyclohexyl), 4.21 (m, 1H, CH-cyclohexyl), 1.03-1.84 (m, 
10H, CH2-cyclohexyl). 13C NMR (75.5 MHz, DMSO-d6): d 
141.6 (C-1), 138.9 (C-3), 115.8 (C-4), 128.7 (C-4a), 121.1 
(C-4b), 122.2 (C-5), 120.4 (C-6), 129.2 (C-7), 112.8 (C-8), 
140.3 (C-8a), 133.8 (C-9a), 130.0 (C-1’), 128.5 (C-2’/6’), 
128.9 (C-3’/5’), 128.8 (C-4’), 177.6 (C-2”), 166.8 (C-5”), 
65.3 (CH2-exocyclic), 53.7 (CH-cyclohexyl), 29.1 (CH2-
cyclohexyl), 25.0 (CH2-cyclohexyl). EIMS, 70 eV, m/z (rel. 
int., %): 455 (5, M+·), 243 (100), 183 (10), 102 (25), 55 (30).
1-(3-Nitrophenyl)-3-[3-cyclohexylamino(methyl)-2-thioxo-
1,3,4-oxadiazol-5-yl] b-carboline (4b)
Yield: 83%, mp 222.0-223.0 oC. IR (KBr) n
max
/cm-1: 
3064 (N–H), 1613 (C=N), 1346 and 1239 (C=S), 1559, 
1485 and 1459 (C=C). 1H NMR (300 MHz, DMSO-d6): 
d 9.00 (s, 1H, H-4), 8.55 (d, J 7.8 Hz, 1H, H-5), 7.37 (t, J 
7.8 Hz, 1H, H-6), 7.63-7.73 (m, 2H, H-7 and H-8), 12.17 
(s, 1H, 9-NH), 8.82 (brs, 1H, H-2’), 8.50 (d, J 8.1 Hz, 1H, 
H-4’), 7.97 (t, J 8.1 Hz, 1H, H-5’), 8.44 (d, J 8.1 Hz,1H, 
H-6’), 6.02 (brs, 2H, CH2-exocyclic), 11.46 (brs, 1H, NH-
cyclohexyl-), 4.22 (m, 1H, CH-cyclohexyl), 1.03-1.85 (m, 
10H, CH2-cyclohexyl). 13C NMR (75.5 MHz, DMSO-d6): d 
141.7 (C-1), 139.1 (C-3), 116.7 (C-4), 121.0 (C-4b), 122.4 
(C-5), 120.6 (C-6), 129.2 (C-7), 112.7 (C-8), 139.7 (C-8a), 
137.9 (C-9a), 134.1 (C-1’), 123.4 (C-2’), 148.4 (C-3’), 
123.6 (C-4’), 130.5 (C-5’), 134.9 (C-6’), 174.2 (C-2”), 
164.9 (C-5”), 65.4 (CH2-exocyclic), 53.8 (CH-cyclohexyl), 
28.9 (CH2-cyclohexyl), 24.9 (CH2-cyclohexyl), 25.1 (CH2-
cyclohexyl), 24.6 (CH2-cyclohexyl). EIMS, 70 eV, m/z (rel. 
int., %): 500 (5, M+·), 242 (60), 183 (30), 102 (100), 55 (90).
1-(4-N,N-Dimethylaminophenyl-3-[3-cyclohexylamino 
(methyl)-2-thioxo-1,3,4-oxadiazol-5-yl] b-carboline (4c)
Yield: 70%, mp 173.0-175.0 oC. IR (KBr) n
max
/cm-1: 
3083 (N–H), 1609 (C=N), 1361 and 1240 (C=S), 1555, 
1489 and 1450 (C=C). 1H NMR (300 MHz, DMSO-d6): 
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d 8.81 (s, 1H, H-4), 8.42 (d, J 7.8 Hz, 1H, H-5), 7.32 (t, 
J 7.8 Hz, 1H, H-6), 7.60 (t, J 7.8 Hz, 1H, H-7), 7.71 (d, 
J 9.0 Hz, 1H, H-8), 11.88 (s, 1H, 9 -NH), 7.97 (d, J 9.0 
Hz, 1H, H-2’), 6.96 (d, J 9.0 Hz, 1H, H-3’), 6.96 (d, J 
9.0 Hz, 1H, H-5’), 7.97 (d, J 9.0 Hz, 1H, H-6’), 3.05 (s, 
6H, N(CH3)2), 5.99 (brs, 2H, CH2-exocyclic), 11.41 (brs, 
1H, NH-cyclohexyl), 4.21 (m, 1H, CH-cyclohexyl), 1.03-
1.84 (m, 10H, CH2-cyclohexyl). 13C NMR (75.5 MHz, 
DMSO-d6): d 141.4 (C-1), 138.7 (C-3), 114.6 (C-4), 124.9 
(C-4a), 121.2 (C-4b), 122.0 (C-5), 120.3 (C-6), 128.5 (C-
7), 112.7 (C-8), 141.2 (C-8a), 133.4 (C-9a), 129.4 (C-1’), 
129.3 (C-2’), 112.1 (C-3’), 150.8 (C-4’), 112.1 (C-5’), 
129.3 (C-6’), 174.2 (C-2”), 39.9 -N(CH3)2, 65.4 (CH2-
exocyclic), 53.7 (CH-cyclohexyl), 29.1 (CH2-cyclohexyl), 
25.0 (CH2-cyclohexyl). EIMS, 70 eV, m/z (rel. int., %): 498 
(5, M+·), 183 (5), 83 (55), 57 (100).
1-Phenyl-3-[3-benzylamino(methyl)-2-thioxo-1,3,4-
oxadiazol-5-yl] b-carboline (5a)
Yield: 79%, mp 225.0-228.0 oC. IR (KBr) n
max 
/cm-1: 
3062 (N–H), 1618 (C=N), 1396 and 1237 (C=S), 1565, 
1493, and 1454 (C=C). 1H NMR (300 MHz, DMSO-d6): 
d 8.91 (s, 1H, H-4), 8.45 (d, J 7.8 Hz, 1H, H-5), 7.31-7.38 
(m, 1H, H-6), 7.60-7.64 (m, 1H, H-7), 7.70 (d, J 7.8 Hz, 
1H, H-8), 11.96 (brs, 1H, 9-NH), 7.89 (d, J 6.9 Hz, 2H, 
H-2’ and H-6’), 7.60 - 7.64 (m, 3H, H-3’, H-4’ and H-5’), 
5.78 (brs, 2H, CH2-exocyclic), 11.74 (brs, 1H, NH-benzyl), 
4.85 (s, 2H, CH2-benzyl), 7.31-7.38 (m, 3H, CH-benzyl), 
7.42 (d, J 3.6 Hz, 2H, CH-benzyl). 13C NMR (75.5 MHz, 
DMSO-d6): d 141.6 (C-1), 138.6 (C-3), 115.9 (C-4), 129.9 
(C-4a), 121.0 (C-4b), 122.2 (C-5), 120.4 (C-6), 129.1 (C-
7), 112.7 (C-8), 140.4 (C-8a), 137.4 (C-9a), 133.9 (C-1’), 
128.4 (C-2’/6’), 129.0 (C-3’/5’), 128.9 (C-4’), 175.1 (C-2”), 
160.1 (C-5”), 67.7 (CH2-exocyclic), 47.7 (CH2-benzyl), 
135.4 (C-benzyl), 128.2 (CH-benzyl), 128.8 (CH-benzyl), 
128.0 (CH-benzyl). EIMS, 70 eV, m/z (rel. int., %): 463 
(10, M+·), 344 (95), 242 (45), 191 (35), 91 (100).
1-(3-Nitrophenyl)-3-[3-benzylamino(methyl)-2-thioxo-
1,3,4-oxadiazol-5-yl] b-carboline (5b)
Yield: 77%, mp 216.0-220.0 oC. IR (KBr) n
max
/cm-1: 
3063 (N–H), 1621 (C=N), 1348 and 1240 (C=S), 1566, 
1496 and 1454 (C=C). 1H NMR (300 MHz, DMSO-d6): d 
8.98 (s, 1H, H-4), 8.48 (d, J 7.5 Hz, 1H, H-5), 7.30-7.40 
(m, 1H, H-6), 7.62 - 7.71 (m, 2H, H-7 and H-8), 12.14 (s, 
1H, 9-NH), 8.71 (brs, 1H, H-2’), 8.43 (dd, J 7.2 and 1.8 Hz, 
1H, H-4’), 7.91 (t, J 7.2 Hz, 1H, H-5’), 8.32 (d, J 7.2 Hz, 
1H, H-6’), 5.79 (brs, 2H, CH2-exocyclic), 11.78 (brs, 1H, 
NH-benzyl), 4.82 (s, 2H, CH2-benzyl), 7.29-7.40 (m, 5H, 
CH-benzyl). 13C NMR (75.5 MHz, DMSO-d6): d 142.1 (C-
1), 138.8 (C-3), 116.7 (C- 4), 127.8 (C-4a), 121.0 (C-4b), 
122.4 (C-5), 120.7 (C-6), 129.2 (C-7), 112.6 (C-8), 141.6 
(C-8a), 134.8 (C-9a), 134.1 (C-1’), 123.2 (C-2’), 148.2 (C-
3’), 123.6 (C-4’), 130.4 (C-5’), 135.4 (C-6’), 176.4 (C-2”), 
160.2 (C-5”), 67.8 (CH2-exocyclic), 47.7 (CH2-benzyl), 
137.9 (C-benzyl), 128.0 (CH-benzyl), 128.6 (CH-benzyl), 
127.8 (CH-benzyl). EIMS, 70 eV, m/z (rel. int., %): 509 (5, 
M+·), 191 (10), 91 (100), 65 (15).
1-(4-N,N-Dimethylaminophenyl)-3-[3-benzylamino 
(methyl)-2-thioxo-1,3,4-oxadiazol-5-yl] b-carboline (5c)
Yield: 86%, mp 200.0-205.0 oC. IR (KBr) n
max
/cm-1: 
3086 (N–H), 1607 (C=N), 1363 and 1241 (C=S), 1558, 
1495 and 1443 (C=C). 1H NMR (300 MHz, DMSO-d6): 
d 8.79 (s, 1H, H-4), 8.40 (d, J 7.8 Hz, 1H, H-5), 7.28-7.39 
(m, 1H, H-6), 7.59 (t, J 7.8 Hz, 1H, H-7), 7.68-7.76 (m, 3H, 
H-8, H-2’ and H-6’), 11.84 (s, 1H, 9-NH), 6.86 (d, J 8.4 Hz, 
2H, H-3’ and H-5’), 3.06 (s, 6H, N(CH3)2), 5.80 (brs, 2H, 
CH2-exocyclic), 4.86 (s, 2H, CH2-benzyl), 7.43 (d, J 4.5 Hz, 
CH-benzyl), 7.28-7.39 (m, 3H, CH-benzyl). 13C NMR (75.5 
MHz, DMSO-d6): d 141.4 (C-1), 135.4 (C-3), 114.7 (C-4), 
124.8 (C-4a), 121.2 (C-4b), 122.0 (C-5), 120.3 (C-6), 128.5 
(C-7), 112.8 (C-8), 141.1 (C-8a), 133.4 (C-9a), 129.3 (C-1’), 
129.1 (C- 2’/6’), 112.1 (C-3’/5’), 150.7 (C-4’), 175.1 (C-2”), 
160.1 (C-5”), 40.0 -N(CH3)2, 67.8 (CH2-exocyclic), 47.8 
(CH2-benzyl), 138.4 (C-benzyl), 128.8 (CH-benzyl), 128.2 
(CH-benzyl), 127.9 (CH-benzyl). EIMS, 70 eV, m/z (rel. int., 
%): 506 (5, M+·), 242 (45), 191 (35), 91 (100).
1-Phenyl-3-[3-pyrrolidylamino(methyl)-2-thioxo-1,3,4-
oxadiazol-5-yl] b-carboline (6a) 
Yield: 55%, mp 207.0-209.0 oC. IR (KBr) n
max
/cm-1: 
3280 (N-H), 1622 (C=N), 1374 and 1243 (C=S), 1567, 
1496, 1445 and 1415 (C=C). 1H NMR (300 MHz, 
DMSO-d6): d 8.87 (s, 1H, H-4), 8.50 (d, J 7.8 Hz, 1H, 
H-5), 7.35 (t, J 7.8 Hz, 1H, H-6), 7.57 - 7.72 (m, H-7, 
H-8, H-3’, H- 4’ and H-5’), 11.99 (brs, 1H, 9-NH), 8.05 
(d, J 6.9 Hz, 2H, H-2’ and H-6’), 5.20 (brs, 2H, CH2-
exocyclic), 2.89 (brs, 4H, CH2-pyrrolidyl), 1.71 (brs, 4H, 
CH2-pyrrolidyl).13C NMR (75.5 MHz, DMSO-d6): d 142.8 
(C-1), 137.2 (C-3), 113.9 (C-4), 120.9 (C-4b), 122.4 (C-5), 
120.5 (C-6), 129.5 (C-7), 112.8 (C-8), 141.6 (C-8a), 134.0 
(C-9a), 131.1 (C-1’), 128.6 (C-2’/6’), 128.9 (C-3’/5’), 
129.2 (C-4’), 177.8 (C-2”), 159.5 (C-5”), 66.1 (CH2-
exocyclic), 49.5 (CH2-pyrrolidyl), 23.6 (CH2-pyrrolidyl). 
EIMS, 70 eV, m/z (rel. int., %): 427 (5, M+·), 243 (100), 
189 (10), 121 (40).
1-(3-Nitrophenyl)-3-[3-pyrrolidylamino(methyl)-2-thioxo-
1,3,4-oxadiazol-5-yl] b-carboline (6b)
Yield: 52%, mp 112.0-114.0 oC. IR (KBr) n
max
/cm-1: 
3285 (N-H), 1623 (C=N), 1347 and 1252 (C=S), 1523, 
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1498 and 1455 (C=C). 1H NMR (300 MHz, DMSO-d6): 
d 8.95 (s, 1H, H-4), 8.54 (d, J 7.8 Hz, 1H, H-5), 7.37 (t, J 
7.8 Hz, 1H, H-6), 7.63-7.72 (m, 2H, H-7 and H-8), 12.17 
(s, 1H, 9-NH), 8.80 (s, 1H, H-2’), 8.50 (d, J 7.8 Hz, 1H, 
H-4’), 7.96 (t, J 7.8 Hz, 1H, H-5’), 8.44 (d, J 7.8 Hz, 1H, 
H-6’), 5.20 (brs, 2H, CH2-exocyclic), 2.89 (brs, 4H, CH2- 
pyrrolidyl), 1.71 (brs, 4H, CH2-pyrrolidyl). 13C NMR (75.5 
MHz, DMSO-d6): d 141.7 (C-1), 138.6 (C-3), 130.1 (C-4), 
120.9 (C-4b), 122.5 (C-5), 120.7 (C-6), 129.3 (C-7), 112.7 
(C-8), 140.2 (C-8a), 134.1 (C-9a), 131.4 (C-1’), 123.4 
(C-2’), 148.2 (C-3’), 123.7 (C-4’), 130.6 (C-5’), 135.1 
(C-6’), 177.9 (C-2”),159.3 (C-5”), 66.2 (CH2-exocyclic), 
49.5 (CH2-pyrrolidyl), 23.6 (CH2-pyrrolidyl). EIMS, 70 eV, 




Yield: 92%, mp 156.0-160.0 oC. IR (KBr) n
max
/cm-1: 
3080 (N-H), 1623 (C=N), 1369 and 1243 (C=S), 1557, 1497 
and 1455 (C=C). 1H NMR (300 MHz, DMSO-d6): d 8.74 
(s, 1H, H-4), 8.46 (d, J 8.1 Hz, 1H, H-5), 7.32 (t, J 8.1 Hz, 
1H, H-6), 7.60 (t, J 8.1 Hz, 1H, H-7), 7.71 (d, J 8.1, 1H, 
H-8), 11.87 (s, 1H, 9-NH), 7.96 (d, J 9.0 Hz, 1H, H-2’), 
6.97 (d, J 9.0 Hz, 1H, H-3’), 6.96 (d, J 9.0 Hz, 1H, H-5’), 
7.96 (d, J 9.0 Hz, 1H, H-6’), 3.05 (s, 1H, N(CH3)2), 5.20 
(brs, 2H, CH2-exocyclic), 2.89 (brs, 4H, CH2-pyrrolidyl), 
1.71 (brs, 4H, CH2-pyrrolidyl). 13C NMR (75.5 MHz, 
DMSO-d6): d 143.5 (C-1), 133.5 (C-3), 112.7 (C-4), 124.6 
(C-4a), 121.0 (C-4b), 122.1 (C-5), 120.3 (C-6), 128.6 (C-
7), 112.8 (C-8), 141.4 (C-8a), 130.8 (C-9a), 129.0 (C-1’), 
129.4 (C-2’), 112.1 (C-3’), 150.9 (C-4’), 112.1 (C-5’), 
129.4 (C-6’), 177.6 (C-2”), 163.7 (C-5”), 40.0 -N(CH3)2, 
66.1 (CH2-exocyclic), 49.5 (CH2-pyrrolidyl), 23.6 (CH2-
pyrrolidyl). EIMS, 70 eV, m/z (rel. int., %): 470 (10, M+·), 
287 (100), 120 (35).
1-Phenyl-3-[3-morpholylamino(methyl)-2-thioxo-1,3,4-
oxadiazol-5-yl] b-carboline (7a)
Yield: 82%, mp 208.0-210.0 oC. IR (KBr) n
max
/cm-1: 
3207 (N-H indol), 1622 (C=N), 1359 and 1248 (C=S), 
1561, 1496 and 1455 cm-1 (C=C). 1H NMR (300 MHz, 
DMSO-d6): d 8.90 (s, 1H, H-4), 8.52 (d, J 7.8 Hz, 1H, 
H-5), 7.35 (t, J 7.8, 1H, H-6), 7.58-7.73 (m, 5H, H-7, H-8, 
H-3’, H-4’ and H-5’), 12.03 (s, 1H, 9-NH), 8.05 (d, J 6.9 
Hz, 1H, H-2’ and H-6’), 5.08 (brs, 2H, CH2-exocyclic), 
2.81 (t, J 4.3 Hz, 4H, CH2-morpholyl), 3.61 (t, J 4.3 Hz, 
4H, CH2-morpholyl). 13C NMR (75.5 MHz, DMSO-d6): d 
143.0 (C-1), 137.2 (C-3), 114.3 (C-4), 129.0 (C-4a), 120.9 
(C-4b), 122.4 (C-5), 120.5 (C-6), 129.5 (C-7), 112.8 (C-8), 
141.6 (C-8a), 134.1 (C-9a), 130.6 (C-1’), 128.6 (C-2’/6’), 
128.9 (C-3’/5’), 129.3 (C-4’), 177.6 (C-2”), 161.2 (C-5”), 
70.0 (CH2-exocyclic), 50.1 (CH2-morpholyl), 66.4 (CH2-
morpholyl). EIMS, 70 eV, m/z (rel. int., %): 443 (5, M+·), 
243 (100), 121 (20), 58 (25).
1-(3-Nitrophenyl)-3-[3-morpholylamino(methyl)-2-thioxo-
1,3,4-oxadiazol-5-yl] b-carboline (7b)
Yield: 85%, mp 163.0-167.0 oC. IR (KBr) n
max
/cm-1: 
3226 (N-H), 1626 (C=N), 1351 and 1249 (C=S), 1559, 
1497 and 1453 (C=C). 1H NMR (300 MHz, DMSO-d6): d 
8.98 (s, 1H, H-4), 8.55 (d, J 7.8 Hz, 1H, H-5), 7.38 (t, J 7.8 
Hz, 1H, H-6), 7.64-7.73 (m, 2H, H-7, H-8), 12.21 (s, 1H, 
9-NH), 8.80 (s, 1H, H-2’), 8.50 (d, J 7.8 Hz, 1H, H-4’), 
7.97 (t, J 7.8 Hz, 1H, H-5’), 8.45 (dd, J 7.8 and 1.8 Hz, 2H, 
H-6’), 5.09 (brs, 2H, CH2-exocyclic), 2.81 (brs, 4H, CH2-
morpholyl), 3.61 (brs, CH2-morpholyl). 13C NMR (75.5 
MHz, DMSO-d6): d 141.7 (C-1), 148.2 (C-3), 115.0 (C-4), 
122.6 (C-5), 120.8 (C-6), 129.4 (C-7), 112.7 (C-8), 140.4 
(C-8a), 134.3 (C-9a), 130.1 (C-1’), 123.4 (C-2’), 148.2 (C-
3’), 123.8 (C-4’), 130.6 (C-5’), 135.1 (C-6’), 177.7 (C-2”), 
160.6 (C-5”), 70.0 (CH2-exocyclic), 50.1 (CH2-morpholyl), 
66.0 (CH2-morpholyl).EIMS, 70 eV, m/z (rel. int., %): 488 
(5, M+·), 289 (95), 242 (100), 121 (20), 57 (25).
1-(4-N,N-Dimethylaminophenyl)-3-[3-morpholylamino 
(methyl)-2-thioxo-1,3,4-oxadiazol-5-yl] b-carboline (7c)
Yield: 83%, mp 215.0-217.0 oC. IR (KBr) n
max
/cm-1: 
3261 (N-H), 1609 (C=N), 1364 and 1238 (C=S), 1556, 
1495 and 1438 (C=C). 1H NMR (300 MHz, DMSO-d6): 
d 8.75 (s, 1H, H-4), 8.46 (d, J 8.1 Hz, 1H, H-5), 7.33 (t, 
J 8.1 Hz, 1H, H-6), 7.60 (t, J 8.1 Hz, H-7), 7.72 (d, J 8.1 
Hz, 1H, H-8), 11.90 (s, 1H, 9-NH), 7.96 (d, J 8.7 Hz, 
1H, H-2’), 6.97 (d, J 8.7 Hz, 1H, H-3’), 6.97 (d, J 8.7 
Hz, 1H, H-5’), 7.96 (d, J 8.7 Hz, 1H, H-6’), 3.05 (s, 6H, 
N(CH3)2), 5.08 (brs, 2H, CH2-exocyclic), 2.81 (brs, 4H, 
CH2-morpholyl), 3.61 (brs, CH2-morpholyl). 13C NMR 
(75.5 MHz, DMSO-d6): d 143.6 (C-1), 133.6 (C-3), 112.9 
(C-4), 124.5 (C-4a), 121.0 (C-4b), 122.1 (C-5), 120.4 
(C-6), 128.6 (C-7), 112.8 (C-8), 141.4 (C-8a), 130.7 
(C-9a), 128.9 (C-1’), 129.4 (C-2’), 112.1 (C-3’), 150.9 
(C-4’), 112.1 (C-5’), 129.4 (C-6’), 177.6 (C-2”), 161.4 
(C-5”), 39.9 - N(CH3)2, 69.9 (CH2-exocyclic), 50.1 (CH2-
morpholyl), 66.0 (CH2-morpholyl). EIMS, 70 eV, m/z 
(rel. int., %): 486 (5, M+·), 242 (30), 121 (15), 57 (100).
Anticancer assays 
The synthesized compounds were evaluated in vitro 
against eight-cell panel lines consisting of melanoma 
(UACC-62), breast (MCF7), ovarian resistant (NCI/ADR), 
renal (786-0), lung (NCI-460), prostate (PCO-3), ovarian 
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(OVCAR) and colon (HT-29). The tests were performed by 
the colorimetric method with sulforodamine B, according to 
NCI standard protocol and doxorubicin was used as positive 
control.22 Assays were performed in a 96-well plate using 
four concentrations at 10-fold dilutions (0.25 mg mL-1 
to 250 mg mL-1) for each test compound. The anticancer 
activity was deduced from concentration-response curves 
and three concentration response parameters (GI50, TGI and 
LC50) were calculated. The GI50 values (growth inhibitory 
activity) (Table 1) refer to the drug concentration that 
produce 50% reduction of cellular growth when compared 
to untreated control cells.23 The TGI (cytostatic activity) 
and LC50 (cytotoxic activity) values parameters (Table 2) 
refer to the drug concentration for total growth inhibition 
and for killing 50% of cells, respectively. Compounds 
with GI50 values < 100 mmol L-1 were considered active. A 
mean graph midpoint values (MG-MID) of the compounds 
toward tumor cell lines were calculated for each of the 
parameters GI50, TGI and LC50. MG-MID values supplied 
an averaged activity parameter for all cell lines.23
Antimicrobial activity
The bacterial strains were grown overnight at 36 oC 
in Nutrient Agar (Merck), and the strains were grown in 
Saboraud Dextrose Agar. Inoculum for the assays was 
prepared by diluting scraped cell mass in 0.85% NaCl 
solution, adjusted to McFarland scale 0.5 and confirmed by 
spectrophotometrical reading at 580 nm. Cell suspensions 
were finally diluted to 104 UFC mL-1 for use in the activity 
assays. Minimal Inhibitory Concentration (MIC) tests were 
carried out using Müller-Hinton broth (bacteria) or RPMI-
1640 (yeasts) on a tissue culture test plate (96 wells).24 Each 
compound was tested in duplicate. The stock solutions of 
compounds firstly in DMSO and subsequently in Tween 
80 water solution (0.1%) were diluted and transferred 
into the first well, and serial dilutions were performed so 
that concentrations in the range of 250-1.6 mg mL-1 were 
obtained. Chloramphenicol and nystatin (Merck) were used 
as the reference antibiotic control. The inoculum was added 
to all wells and the plates were incubated at 36 oC for 24h. 
Antibacterial activity was detected by adding 20 µL of 
0.5% TTC (triphenyl tetrazolium chloride, Merck) aqueous 
solution. MIC was defined as the lowest concentration of 
the compounds that inhibited visible growth, as indicated 
by TTC staining (dead cells are not stained by TTC). For 
antifungal activity evaluation, after the incubation period 
changes in the RPMI-1640 medium color were verified 
from pink (original color) to yellow. The change indicates 
an acidification from medium by the microorganisms’ 
growth.25 
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Figure S1. 1H NMR spectra (300 MHz, DMSO-d6) of compound 1a. 
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Figure S2. 13C NMR / DEPT spectra (75.5 MHz, DMSO-d6) of compound 1a. 
Figure S3. 1H NMR spectra (300 MHz, DMSO-d6) of compound 1b. 
Savariz et al. S3Vol. 21, No. 2, 2010
Figure S5. 1H NMR spectra (300 MHz, DMSO-d6) of compound 1c. 
Figure S4. 13C NMR / DEPT spectra (75.5 MHz, DMSO-d6) of compound 1b. 
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Figure S6. 13C NMR / DEPT spectra (75.5 MHz, DMSO-d6) of compound 1c.
Figure S7. 1H NMR spectra (300 MHz, DMSO-d6) of compound 2a. 
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Figure S9. 1H NMR spectra (300 MHz, DMSO-d6) of compound 2b. 
Figure S8. 13C NMR / DEPT spectra (75.5 MHz, DMSO-d6) of compound 2a. 
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Figure S10. 13C NMR / DEPT spectra (75.5 MHz, DMSO-d6) of compound 2b. 
Figure S11. HMQC spectra of compound 2b.
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Figure S12. 1H NMR spectra (300 MHz, DMSO-d6) of compound 2c. 
Figure S13. 13C NMR / DEPT spectra (75.5 MHz, DMSO-d6) of compound 2c. 
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Figure S14. 1H NMR spectra (300 MHz, DMSO-d6) of compound 3a. 
Figure S15. 13C NMR / DEPT spectra (75.5 MHz, DMSO-d6) of compound 3a. 
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Figure S16. HMQC spectra of compound 3a.
Figure S17. 1H NMR spectra (300 MHz, DMSO-d6) of compound 3b. 
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Figure S18. 13C NMR / DEPT spectra (75.5 MHz, DMSO-d6) of compound 3b.
Figure S19. HMQC spectra of compound 3b.
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Figure S20. 1H NMR spectra (300 MHz, DMSO-d6) of compound 3c.
Figure S21. 13C NMR / DEPT spectra (75.5 MHz, DMSO-d6) of compound 3c. 
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Figure S22. HMQC spectra of compound 3c.
Figure S23. 1H NMR spectra (300 MHz, DMSO-d6) of compound 4a. 
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Figure S24. 13C NMR / DEPT spectra (75.5 MHz, DMSO-d6) of compound 4a. 
Figure S25. HMQC spectra of compound 4a.
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Figure S26. 1H NMR spectra (300 MHz, DMSO-d6) of compound 4b.
Figure S27. 13C NMR / DEPT spectra (75.5 MHz, DMSO-d6) of compound 4b. 
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Figure S28. HMQC spectra of compound 4b.
Figure S29. 1H NMR spectra (300 MHz, DMSO-d6) of compound 4c.
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Figure S30. 13C NMR / DEPT spectra (75.5 MHz, DMSO-d6) of compound 4c.
Figure S31. HMQC spectra of compound 4c.
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Figure S32. 1H NMR spectra (300 MHz, DMSO-d6) of compound 5a.
Figure S33. 13C NMR / DEPT spectra (75.5 MHz, DMSO-d6) of compound 5a. 
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Figure S34. HMQC spectra of compound 5a.
Figure S35. 1H NMR spectra (300 MHz, DMSO-d6) of compound 5b. 
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Figure S36. 13C NMR / DEPT spectra (75.5 MHz, DMSO-d6) of compound 5b.
Figure S37. HMQC spectra of compound 5b.
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Figure S38. 1H NMR spectra (300 MHz, DMSO-d6) of compound 5c. 
Figure S39. 13C NMR / DEPT spectra (75.5 MHz, DMSO-d6) of compound 5c. 
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Figure S40. HMQC spectra of compound 5c.
Figure S41. 1H NMR spectra (300 MHz, DMSO-d6) of compound 6a. 
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Figure S42. 13C NMR / DEPT spectra (75.5 MHz, DMSO-d6) of compound 6a. 
Figure S43. HMQC spectra of compound 6a.
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Figure S44. 1H NMR spectra (300 MHz, DMSO-d6) of compound 6b.
Figure S45. 13C NMR / DEPT spectra (75.5 MHz, DMSO-d6) of compound 6b.
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Figure S46. HMQC spectra of compound 6b.
Figure S47. 1H NMR spectra (300 MHz, DMSO-d6) of compound 6c.
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Figure S49. 1H NMR spectra (300 MHz, DMSO-d6) of compound 7a.
Figure S48. 13C NMR / DEPT spectra (75.5 MHz, DMSO-d6) of compound 6c.
Synthesis, Antitumor and Antimicrobial Activity J. Braz. Chem. Soc.S26
Figure S50. 13C NMR / DEPT spectra (75.5 MHz, DMSO-d6) of compound 7a. 
Figure S51. HMQC spectra of compound 7a.
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Figure S52. 1H NMR spectra (300 MHz, DMSO-d6) of compound 7b. 
Figure S53. 1H NMR spectra (300 MHz, DMSO-d6) of compound 7b.
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Figure S54. HMQC spectra of compound 7b.
Figure S55. 1H NMR spectra (300 MHz, DMSO-d6) of compound 7c.
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Figure S56. 13C NMR / DEPT spectra (75.5 MHz, DMSO-d6) of compound 7c. 
